Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb neoadjuvant TEC chemotherapy in HER2-negative primary breast cancer
2008-003064-19Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Oct 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, epirubicin and cyclophosphamide in breast cancer, sponsored by Leipzig University. Primary endpoint: Pathological complete response in the breast. Started Oct 2008; status: completed.
02
Drugs
docetaxelepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-003064-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003064-19.